Renflexis (infliximab-abda) — FDA-Approved Biosimilar to Remicade (infliximab)

TNF-alpha Inhibitor Biosimilar (IV) · Approved 2017 · $0–$35/mo for most insured patients

🔬 What Is Renflexis?

Renflexis (infliximab-abda) is an FDA-approved biosimilar to Remicade (infliximab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Renflexis (infliximab-abda) is an FDA-approved Remicade biosimilar from Samsung Bioepis and Organon. Like Remicade, it is administered by IV infusion every 4–8 weeks depending on the condition. It is approved for all Remicade indications and may offer cost savings.

🛒 Order Renflexis — Direct from BiologicHealthPlus

Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.

With Insurance

$0–$35/mo for most insured patients

Organon Patient Support

Uninsured / PAP

Free

Income-based assistance

Start My Order → 💬 WhatsApp 📞 Call

Renflexis Overview

Property	Details
Brand Name	Renflexis
Generic Name	infliximab-abda
Reference Biologic	Remicade (infliximab)
Manufacturer	Samsung Bioepis/Organon
Drug Class	TNF-alpha Inhibitor Biosimilar (IV)
FDA Approval	2017
Route	IV infusion
Approved Conditions	Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis
Copay Program	Organon Patient Support — $0–$35/mo for most insured patients

Approved Conditions

✓Rheumatoid Arthritis✓Ankylosing Spondylitis✓Psoriatic Arthritis✓Plaque Psoriasis✓Crohn's Disease✓Ulcerative Colitis

Renflexis vs Remicade (infliximab)

Renflexis has been demonstrated to be biosimilar to Remicade (infliximab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Remicade (infliximab) should discuss any potential switch to Renflexis with their prescriber.

Factor	Renflexis	Remicade (infliximab)
FDA Status	Biosimilar (approved 2017)	Reference biologic
Active Ingredient	infliximab-abda	infliximab
Mechanism	TNF-alpha Inhibitor)	Same
Approved Indications	Same as Remicade (infliximab)	Multiple FDA-approved
Typical Patient Cost	$0–$35/mo for most insured patients	$0–$35/mo (varies by plan)

Yes. The FDA requires biosimilars to demonstrate there are no clinically meaningful differences in safety, purity, and potency compared to the reference product. Renflexis underwent rigorous clinical studies demonstrating biosimilarity to Remicade (infliximab). Your prescriber can discuss whether Renflexis is appropriate for your specific situation.

Many patients do switch from reference biologics to biosimilars. The decision should be made in consultation with your prescriber. Switching is generally safe for stable patients, but your doctor may want to monitor you during the transition. BiologicHealthPlus can coordinate the prior authorization for Renflexis and ensure a seamless supply transition.

Most commercial insurance plans and Medicare Part D cover Renflexis with prior authorization. In many cases, Renflexis may have a lower tier placement on formularies than Remicade (infliximab), potentially reducing your copay. BiologicHealthPlus verifies your insurance coverage, handles all prior authorization, and enrolls you in the Organon Patient Support copay program to minimize your out-of-pocket costs.

Without insurance, Renflexis costs approximately $4700/month at list price — lower than Remicade (infliximab)'s list price. Uninsured or underinsured patients may qualify for patient assistance through Organon Patient Support. BiologicHealthPlus will find every available savings option for you at no charge.

📚 Sources & Further Reading

🔗

FDA Biosimilar ApprovalsFDA

🔗

BiosimilarWikipedia

🔗

ACR Biosimilar PositionACR

🔗

Biosimilar DevelopmentNIH/NCBI

🔗

Medicare Biosimilar CoverageCMS

Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.

Medical Disclaimer: This page is for informational purposes only. Renflexis requires a valid prescription. Consult your physician before making any changes to your medication. Last updated: August 2026.